Correlation Between Oncopeptides and Immunovia Publ

Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Immunovia Publ at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Immunovia Publ into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncopeptides AB and Immunovia publ AB, you can compare the effects of market volatilities on Oncopeptides and Immunovia Publ and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Immunovia Publ. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Immunovia Publ.

Diversification Opportunities for Oncopeptides and Immunovia Publ

0.32

Correlation Coefficient

Oncopeptides  Immunovia Publ

Weak diversification

The 3 months correlation between Oncopeptides and Immunovia is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Immunovia publ AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunovia publ AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Immunovia Publ. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunovia publ AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Immunovia Publ go up and down completely randomly.

Pair Corralation between Oncopeptides and Immunovia Publ

Assuming the 90 days trading horizon Oncopeptides AB is expected to under-perform the Immunovia Publ. But the stock apears to be less risky and, when comparing its historical volatility, Oncopeptides AB is 2.54 times less risky than Immunovia Publ. The stock trades about -0.07 of its potential returns per unit of risk. The Immunovia publ AB is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  86.00  in Immunovia publ AB on September 3, 2024 and sell it today you would lose (1.00) from holding Immunovia publ AB or give up 1.16% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Oncopeptides AB  vs.  Immunovia publ AB

Oncopeptides AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Immunovia publ AB

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Immunovia publ AB are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain primary indicators, Immunovia Publ sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Oncopeptides and Immunovia Publ

The main advantage of trading using opposite Oncopeptides and Immunovia Publ positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Immunovia Publ can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovia Publ will offset losses from the drop in Immunovia Publ's long position.

The idea behind Oncopeptides AB and Immunovia publ AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.